Lexicon Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Business context and period. This unaudited filing covers the three and six months ended June 30, 2023. Lexicon is a biopharmaceutical company that began U.S. commercialization of INPEFA (sotagliflozin) following FDA approval in May; shipments to customers began in June. Its pipeline includes LX9211, under development for diabetic peripheral neuropathic pain.
Financial performance
Amounts below are in millions of dollars, except per-share amounts.
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0.317 | $0.035 | $0.340 | $0.072 |
| Operating expenses | $44.557 | $24.042 | $75.722 | $47.459 |
| Operating loss | $44.240 | $24.007 | $75.382 | $47.387 |
| Net loss | $44.904 | $24.587 | $76.838 | $48.063 |
| Net loss per share | $0.22 | $0.16 | $0.39 | $0.32 |
| Operating cash used | Not presented quarterly | Not presented quarterly | $69.730 | $47.843 |
Q2 revenue included $0.291 million of INPEFA product sales; the balance was royalties and other revenue. Product sales were more than 85% of six-month revenue. Cost of sales was $0.008 million for the six-month period. Revenue remains too small relative to expenses for margins to be meaningful.
At June 30, cash and cash equivalents were $102.3 million and short-term investments were $154.5 million, totaling $256.7 million, versus $138.4 million at December 31, 2022. Total assets were $316.7 million; total liabilities were $130.4 million; stockholders’ equity was $186.4 million. Long-term debt, net, was $98.8 million. The company reported $69.7 million of operating cash use and $62.5 million of net investing cash use in the first half, offset by $188.2 million of financing cash inflows.
Material changes and notable items
- Net loss increased $20.3 million in Q2 and $28.8 million for the six-month period year over year, primarily reflecting higher operating expenses and interest expense.
- SG&A rose to $30.0 million in Q2 and $49.1 million for the first half, compared with $10.7 million and $19.2 million, respectively, in 2022. Management attributed the increase mainly to commercial-launch sales-force hiring and higher marketing, professional, travel, training, and software costs.
- R&D was $14.5 million in Q2, up from $13.4 million; first-half R&D was $26.6 million, down from $28.3 million. Launch-related manufacturing and development costs increased, partly offset by lower professional and consulting fees over the six-month period.
- In May, Lexicon issued approximately 55.3 million shares at $2.60 per share in a public offering and concurrent private placement, generating approximately $139.0 million net. The large issuance increased the share count and diluted existing holders.
- Lexicon received $50.0 million net from the third Oxford loan tranche in June. Of the facility’s $150 million capacity, $100 million had been drawn by June 30.
Outlook, risks and contingencies
- Management stated that available unrestricted cash and investments, together with expected collaboration and other revenues, should fund currently planned operations for at least 12 months from the report date. It warned that additional financing may be needed thereafter and may not be available on acceptable terms; reduced financing could delay or scale back trials, commercialization, or R&D.
- No specific revenue, earnings, or product-sales guidance was provided. Future capital needs depend on INPEFA’s commercial launch, clinical and regulatory outcomes, and collaboration income.
- The Oxford loans mature in March 2027 and bear floating interest; the weighted-average rate was 12.7% at June 30. The loans are secured by a first lien on company and subsidiary assets and include financial and other covenants. Lexicon reported compliance at quarter-end. The fourth $25 million tranche is available at Lexicon’s option during December 2023; the fifth $25 million tranche requires Oxford’s consent. Debt service, covenant requirements, and variable rates are material liquidity risks.
- Key business risks include market acceptance, payer coverage and reimbursement, manufacturing and distribution execution for INPEFA, and successful late-stage development and regulatory approval of LX9211. The type 1 diabetes sotagliflozin NDA received an FDA complete response letter; a hearing process concerning potential grounds to deny approval was ongoing.
- Potential payments include $4.5 million in royalties in three annual installments upon type 1 diabetes approval in a major market, and a $5 million LX9211 milestone upon dosing the first patient in a Phase 3 trial. The filing describes ordinary-course legal matters that management does not expect to have a material adverse effect.
Important facts for investors to verify
- INPEFA launch progress: prescriptions, net sales, payer access, rebate levels, and the pace of commercial uptake.
- Cash burn against the $256.7 million cash-and-investment balance, and management’s stated minimum 12-month funding outlook.
- Oxford loan terms, interest-rate exposure, covenant compliance, and whether additional tranches are drawn.
- Development and regulatory milestones for LX9211 and the status of the type 1 diabetes sotagliflozin hearing process.
- Further financing or equity issuance, and its potential effect on dilution and liquidity.